The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1346
Tribenzor for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Many patients with hypertension require more than one drug to control their blood pressure.1 Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar) and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.

CLINICAL STUDY — In a randomized, double-blind clinical trial in 2492 patients with hypertension (mean baseline 169/101 mm Hg), Tribenzor was compared to treatment with all possible pairs of its individual components, all titrated up to their highest strengths (40 mg olmesartan, 10 mg amlodipine ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tribenzor for Hypertension
Article code: 1346c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian